早发性肾细胞癌患者胚系基因检测的突变谱与临床关联
该回顾性研究纳入2003年2月至2020年6月在本机构接受胚系基因检测的232例年龄≤46岁的早发性肾细胞癌患者,其中17.7%检出致病/可能致病性胚系变异,9.1%位于肾细胞癌相关基因,8.6%位于非肾细胞癌相关基因(包括DNA损伤修复基因)。双侧/多灶肾肿瘤、非透明细胞组织学及额外肾外原发恶性肿瘤与肾细胞癌相关基因变异相关。
要点
- 早发性肾细胞癌患者胚系致病/可能致病性变异检出率为17.7%。
- 双侧/多灶、非透明细胞组织学及肾外原发肿瘤提示肾细胞癌相关基因变异。
- 孤立性透明细胞肾细胞癌患者肾细胞癌相关基因变异检出率为0%。
核心结论
- 早发性肾细胞癌患者中遗传性肾细胞癌基因及其他癌症易感基因的胚系致病/可能致病性变异频率较高。
- 当患者具有提示潜在肾细胞癌基因突变的临床表型时,胚系肾细胞癌 panel 检测产出最高。
- 早发性肾细胞癌患者应接受全面的个人史和家族史评估,以指导合适的基因检测。
研究设计与样本
- 回顾性研究,纳入2003年2月至2020年6月在本机构接受胚系基因检测的232例年龄≤46岁的早发性肾细胞癌患者。
- 确定致病/可能致病性变异的频率和谱系,并使用两样本比较(Fisher精确检验或χ2检验)分析突变状态相关的临床特征。
主要发现
- 232例患者中50%为非透明细胞组织学,包括未分类肾细胞癌12.1%、嫌色细胞肾细胞癌9.7%、FH缺陷型肾细胞癌7.0%、乳头状肾细胞癌6.6%和易位相关肾细胞癌4.3%。
- 43.5%的患者有转移性疾病。
- 41例(17.7%)检出胚系致病/可能致病性变异,其中21例(9.1%)位于肾细胞癌相关基因,20例(8.6%)位于非肾细胞癌相关基因,包括17例(7.3%)位于DNA损伤修复基因如BRCA1/2、ATM和CHEK2。
- 与肾细胞癌相关基因致病/可能致病性变异相关的因素包括双侧/多灶肾肿瘤、非透明细胞组织学和额外的肾外原发恶性肿瘤。
- 在仅有孤立性透明细胞肾细胞癌的患者中,肾细胞癌相关基因和非肾细胞癌相关基因的致病/可能致病性变异检出率分别为0%和9.9%。
临床怎么用
- 对早发性肾细胞癌患者应进行全面个人史和家族史评估,以指导基因检测。
- 具有双侧/多灶肾肿瘤、非透明细胞组织学或额外肾外原发恶性肿瘤的早发性肾细胞癌患者,应优先考虑胚系肾细胞癌 panel 检测。
- 孤立性透明细胞肾细胞癌的早发性患者肾细胞癌相关基因变异检出率低,但非肾细胞癌相关基因变异(包括DNA损伤修复基因)仍有检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite guidelines recommending genetic counseling for patients with early-onset renal cell carcinoma (RCC), studies interrogating the spectrum of germline mutations and clinical associations in patients with early-onset RCC are lacking. OBJECTIVE: To define the germline genetic spectrum and clinical associations for patients with early-onset RCC diagnosed at age ≤46 yr who underwent genetic testing. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively identified patients with early-onset RCC who underwent germline testing at our institution from February 2003 to June 2020. OUTCOME MEASUREMENT AND STATISTICAL ANALYSIS: The frequency and spectrum of pathogenic/likely pathogenic (P/LP) variants were determined. Clinical characteristics associated with mutation status were analyzed using two-sample comparison (Fisher's exact or χ2 test). RESULTS AND LIMITATIONS: Of 232 patients with early-onset RCC, 50% had non-clear-cell histology, including unclassified RCC (12.1%), chromophobe RCC (9.7%), FH-deficient RCC (7.0%), papillary RCC (6.6%), and translocation-associated RCC (4.3%). Overall, 43.5% had metastatic disease. Germline P/LP variants were identified in 41 patients (17.7%), of which 21 (9.1%) were in an RCC-associated gene and 20 (8.6%) in a non-RCC-associated gene, including 17 (7.3%) in DNA damage repair genes such as BRCA1/2, ATM, and CHEK2. Factors associated with RCC P/LP variants include bilateral/multifocal renal tumors, non-clear-cell histology, and additional extrarenal primary malignancies. In patients with only a solitary clear-cell RCC, the prevalence of P/LP variants in RCC-associated and non-RCC-associated genes was 0% and 9.9%, respectively. CONCLUSIONS: Patients with early-onset RCC had high frequencies of germline P/LP variants in genes associated with both hereditary RCC and other cancer predispositions. Germline RCC panel testing has the highest yield when patients have clinical phenotypes suggestive of underlying RCC gene mutations. Patients with early-onset RCC should undergo comprehensive assessment of personal and family history to guide appropriate genetic testing. PATIENT SUMMARY: In this study of 232 patients with early-onset kidney cancer who underwent genetic testing, we found a high prevalence of mutations in genes that increase the risk of cancer in both kidneys and other organs for patients and their at-risk family members. Our study suggests that patients with early-onset kidney cancer should undergo comprehensive genetic risk assessment.
引用
- Truong H, Sheikh R, Kotecha R, et al. Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. Eur Urol Oncol. 2021. PMID: 34654685. doi:10.1016/j.euo.2021.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。